Mycobacterium Tuberculosis Detection Compositions for Targeted PCR

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods for detecting Mycobacterium tuberculosis (MTB) are time-consuming, insensitive, and non-specific, particularly in low-income countries, leading to inadequate case detection and rising multi-drug resistant strains, with only 60% global case detection and less than 20% of MDR-MTB cases being appropriately diagnosed.

Innovation Solution

A nucleic acid amplification method using specific primer pairs (SEQ ID NOs: 1 and 2, and SEQ ID NOs: 3 and 4) and probes (SEQ ID NOs: 5 and 6) for detecting MTB in samples, combined with inactivation reagents like isopropanol and sodium hydroxide, followed by real-time PCR to enhance sensitivity and specificity.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If routine cultures are used for MTB detection, then detection can be performed, but the process is time-consuming and can take up to six weeks

Engineering Contradiction:
Improvedetection accuracyVSAvoiddetection time
Core Design Contradiction:
Measurement precisionVSLoss of time

Solution Approach 1:

The patent replaces the traditional mechanical culture method with a molecular biology-based nucleic acid amplification system (PCR). This substitution enables detection within hours rather than weeks, resolving the contradiction between detection accuracy and detection time by using a fundamentally different detection mechanism that does not require waiting for bacterial growth.

Inventive Principle:
Principle #28Mechanics substitution (Replace mechanical system)

2Speed

If microscopic examination of acid-fast smears is used, then rapid detection is achieved, but the method is insensitive and non-specific

Engineering Contradiction:
Improvedetection speedVSAvoiddetection sensitivity and specificity
Core Design Contradiction:
SpeedVSMeasurement precision

Solution Approach 1:

The patent merges the speed advantage of microscopic examination with the sensitivity and specificity of molecular methods by using nucleic acid amplification followed by detection. This combination achieves rapid detection (within hours) while simultaneously providing high sensitivity and specificity through targeted amplification of MTB genomic sequences, resolving the contradiction between speed and measurement precision.

Inventive Principle:
Principle #5Merging (Combining)

3Measurement precision

If molecular tests are developed to improve case detection, then sensitivity and specificity increase, but the cost and complexity increase

Engineering Contradiction:
Improvecase detection accuracyVSAvoidtest system complexity
Core Design Contradiction:
Measurement precisionVSDevice complexity

Solution Approach 1:

The patent segments the detection system into distinct functional modules: sample preparation, nucleic acid extraction, PCR amplification with specific primers and probes, and detection. This segmentation allows each component to be optimized independently and enables modular implementation that can be adapted to different resource settings, reducing overall system complexity while maintaining high detection accuracy.

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

The patent uses specific parameter changes in the form of uniquely designed primer and probe sequences that target MTB-specific genomic regions. By changing the molecular parameters (nucleotide sequences) rather than the fundamental detection approach, the system achieves high specificity and sensitivity without requiring complex equipment or procedures.

Inventive Principle:
Principle #35Parameter changes

4Measurement precision

If more comprehensive testing is performed to detect MDR-MTB, then diagnostic accuracy improves, but the percentage of cases appropriately diagnosed remains low at 19%

Engineering Contradiction:
ImproveMDR-MTB diagnosis accuracyVSAvoidcase detection rate
Core Design Contradiction:
Measurement precisionVSProductivity

Solution Approach 1:

The patent performs preliminary identification of MTB infection using nucleic acid amplification before proceeding to drug susceptibility testing. This preliminary action allows for rapid triage of cases, enabling healthcare systems to prioritize and process MDR-MTB testing more efficiently, thereby improving both diagnostic accuracy and overall case detection productivity.

Inventive Principle:
Principle #10Preliminary action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The method achieves high sensitivity (93%) and specificity (97%) in detecting MTB, especially in smear-negative samples, reducing false negatives and false positives, and is suitable for high-throughput automated detection.

Implementation Method 1

hybridizing a probe to the nucleic acid sequence complementary to the target sequence so as to form a hybrid comprising the probe and the nucleic acid sequence complementary to the target sequence

Methodology Applied
Scientific EffectHybridization:

Implementation Method 2

subjecting the mixture to amplification conditions to generate at least one copy of a nucleic acid sequence complementary to the target sequence

Methodology Applied
Scientific EffectPCR amplification:

Implementation Method 3

inactivation reagents like isopropanol and sodium hydroxide

Methodology Applied
Scientific EffectChemical denaturation:

Implementation Method 4

inactivation reagents like isopropanol and sodium hydroxide

Methodology Applied
Scientific EffectPrecipitation: Precipitation

Data Source

PatentEP4282961B1Compositions for the detection and analysis of mycobacterium tuberculosis
Publication Date: 2025.08.20 ABBOTT MOLECULAR INC
  • EP4282961B1 patent drawingFigure 1
  • EP4282961B1 patent drawingFigure 2~3
  • EP4282961B1 patent drawingFigure 4

AI summary

Provided herein are compositions and methods useful for the detection of MTB. In particular, provided herein are kits, reagents, reaction mixtures, and methods involving such for nucleic acid amplification and detection procedures, which specifically and sensitively detect MTB in samples.